Want to see KR:002630 full AI Analyst Report?
Top Page
ORIENTBIO, Inc.
(002630)
Select Model
Select Model
Rating:57Neutral
Price Target:
₩1,342.00
Action:N/A
Date:10/28/26
The score is held back primarily by very weak technicals (price below all key moving averages, negative MACD, and deeply oversold momentum). Financial performance provides meaningful support due to the TTM rebound in profitability and cash flow and a strong, low-leverage balance sheet, but historical volatility and slight TTM revenue decline limit confidence. Valuation is moderate (P/E ~16.6) and does not materially lift the score.
Positive Factors
Conservative balance sheet
Very low leverage and a substantial equity buffer reduce financial strain and improve resilience through operating volatility. This gives ORIENTBIO greater flexibility to sustain laboratory and diagnostic operations, fund necessary investment, and absorb weaker periods without relying heavily on external financing.
Negative Factors
Declining recent revenue
A roughly 3.7% TTM revenue decline signals that current demand or customer activity has not yet produced durable top-line expansion. Without renewed sales growth, the company may have less operating leverage and fewer resources to offset costs or build a stronger earnings trajectory.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Very low leverage and a substantial equity buffer reduce financial strain and improve resilience through operating volatility. This gives ORIENTBIO greater flexibility to sustain laboratory and diagnostic operations, fund necessary investment, and absorb weaker periods without relying heavily on external financing.
Read all positive factors
ORIENTBIO, Inc. (002630) vs. SPDR S&P 500 ETF (SPY)
Market Cap
₩38.16B
Dividend YieldN/A
Average Volume (3M)48.02K
Price to Earnings (P/E)16.5
Beta (1Y)>-0.01
Revenue Growth-3.47%
EPS Growth98.69%
CountryKR
Employees125
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)77.98
Shares Outstanding29,645,752
10 Day Avg. Volume64,112
30 Day Avg. Volume48,025
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)1.00
Price to Sales (P/S)2.30
P/FCF Ratio125.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ORIENTBIO, Inc. Business Overview & Revenue Model
Company Description
ORIENT BIO Inc. is a South Korean company active within the biotechnology sector. The firm specializes in providing laboratory animals and a range of equipment tailored for research environments. Established in 1959, the company initially operated...
ORIENTBIO, Inc. Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
82
Very Positive
Cash Flow
67
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 28.66B | 29.75B | 29.40B | 28.01B | 28.82B | 26.28B |
| Gross Profit | 5.87B | 3.96B | 7.20B | 9.58B | 9.82B | 9.01B |
| EBITDA | 5.40B | -2.24B | -11.02B | 15.67B | -9.25B | 997.25M |
| Net Income | 2.31B | -4.57B | -13.19B | 12.87B | -12.42B | 34.20B |
Balance Sheet | ||||||
| Total Assets | 83.42B | 81.62B | 84.78B | 96.99B | 81.05B | 104.95B |
| Cash, Cash Equivalents and Short-Term Investments | 38.08B | 32.77B | 32.53B | 41.23B | 35.47B | 59.04B |
| Total Debt | 1.19B | 1.94B | 2.62B | 3.04B | 847.75M | 7.40B |
| Total Liabilities | 11.15B | 13.07B | 12.94B | 11.89B | 9.66B | 21.76B |
| Stockholders Equity | 72.27B | 68.54B | 71.85B | 85.10B | 71.39B | 83.19B |
Cash Flow | ||||||
| Free Cash Flow | 5.90B | 547.86M | -4.04B | 2.83B | 674.30M | 140.53M |
| Operating Cash Flow | 7.09B | 2.60B | 752.29M | 3.76B | 1.16B | 2.35B |
| Investing Cash Flow | -170.46M | -2.62B | 315.65M | -3.12B | -20.66B | 16.77B |
| Financing Cash Flow | -664.22M | -688.56M | -839.60M | -570.35M | -6.79B | -1.13B |
ORIENTBIO, Inc. Technical Analysis
Negative
―
Price Trends
1713.22
Negative
1778.47
Negative
1998.65
Negative
Market Momentum
-120.72
Positive
17.35
Positive
5.49
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:002630, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 1520.10, equal to the 50-day MA of 1713.22, and equal to the 200-day MA of 1998.65, indicating a bearish trend. The MACD of -120.72 indicates Positive momentum. The RSI at 17.35 is Positive, neither overbought nor oversold. The STOCH value of 5.49 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:002630.
ORIENTBIO, Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | ₩613.71B | 13.10 | ― | 0.49% | 51.28% | 124.70% | |
57 Neutral | ₩38.16B | 16.52 | ― | ― | -3.47% | 98.69% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
45 Neutral | ₩253.61B | -2.70 | ― | ― | 84.72% | -480.97% | |
44 Neutral | ₩417.81B | -3.41 | ― | 3.29% | 9.57% | -203.15% | |
43 Neutral | ₩2.52T | -30.15 | ― | ― | 23.25% | -58.35% | |
41 Neutral | ₩48.51B | -0.23 | ― | ― | -64.38% | 10.38% |
* General Sector Average
KR:002630
ORIENTBIO, Inc.
1,288.00
-928.00
-41.88%
KR:005250
GC Corp.
9,130.00
-6,357.18
-41.05%
KR:005690
Pharmicell Co., Ltd
10,230.00
-6,961.53
-40.49%
KR:011000
GeneOne Life Science, Inc.
2,670.00
-7,680.00
-74.20%
KR:302440
SK bioscience Co.,Ltd.
32,150.00
-18,750.00
-36.84%
KR:950210
Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh
4,220.00
-8,460.00
-66.72%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.